Discrepancies in listed adverse drug reactions in pharmaceutical product information supplied by the regulatory authorities in Denmark and the USA

Robert Eriksson, Lise Aagaard, Lars Juhl Jensen, Liza Borisova, Dorte Hørlück, Søren Brunak, Ebba Holme Hansen

    Research output: Contribution to journalJournal articleResearchpeer-review

    262 Downloads (Pure)

    Abstract

    Pharmaceutical product information (PI) supplied by the regulatory authorities serves as a source of information on safe and effective use of drugs. The objectives of this study were to qualitatively and quantitatively compare PIs for selected drugs marketed in both Denmark and the USA with respect to consistency and discrepancy of listed adverse drug reaction (ADR) information. We compared individual ADRs listed in PIs from Denmark and the USA with respect to type and frequency. Consistency was defined as match of ADRs and of ADR frequency or match could not be ruled out. Discrepancies were defined as ADRs listed only in one country or listed with different frequencies. We analyzed PIs for 40 separate drugs from ten therapeutic groups and assigned the 4003 identified ADRs to System Organ Classes (Medical Dictionary for Regulatory Activities [MedDRA] terminology). Less than half of listed ADRs (n = 1874; 47%) showed consistency. Discrepancies (n = 2129; 53%) were split into ADRs listed only in the USA (n = 1558; 39%), ADRs listed only in Denmark (n = 325; 8%) and ADRs listed with different frequencies (n = 246; 6%). The majority of listed ADRs were of the type “gastrointestinal disorders” and “nervous system disorders”. Our results show great differences in PIs for drugs approved in both Denmark and the USA illuminating concerns about the credibility of the publicly available PIs. The results also represent an argument for further harmonization across borders to improve consistency between authority-supplied information.
    Original languageEnglish
    Article numbere00038
    JournalPharmacology Research & Perspectives
    Volume2
    Issue number3
    Number of pages10
    ISSN2052-1707
    DOIs
    Publication statusPublished - 2014

    Bibliographical note

    This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

    Keywords

    • Adverse drug reaction
    • Denmark
    • drug approval
    • drug labeling
    • drug legislation
    • European Medicines Agency
    • Food and Drug Administration
    • Product information
    • Regulatory affairs
    • Summary of Product Characteristics
    • United States

    Cite this